Patients with known human immunodeficiency virus (HIV) or hepatitis B or C are excluded
Participant is known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
12. Known to be human immunodeficiency virus (HIV) positive, hepatitis B, or hepatitis C positive;
Has a known history of or screens positive for Human Immunodeficiency Virus (HIV), active chronic or acute Hepatitis B or Hepatitis C.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C or active hepatitis
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or concurrent illness, unrelated to the tumor, requiring active therapy
Prior or current history of hepatitis B, hepatitis C or human immunodeficiency virus
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C; participants with a history of resolved hepatitis A may be included in the trial
No known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) seropositivity; testing is not required in absence of clinical suspicion
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
Positive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosis
History of human immunodeficiency virus (HIV), interstitial lung disease, active Hepatitis B or Hepatitis C, or ?Grade 3 immune-related AE with prior immunotherapy
Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.
Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Participants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virus
The patient has known positive status for human immunodeficiency virus active or chronic Hepatitis B or Hepatitis C.
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive; hepatitis and HIV testing are not required prior to the start of treatment
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known immunodeficiency, human immunodeficiency virus (HIV) positivity, hepatitis B, or hepatitis C
Positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Human immunodeficiency virus (HIV) positive; active hepatitis B or C;
Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
Subjects with known human immunodeficiency virus (HIV), acute chronic hepatitis B virus surface antigen (HBsAg) or hepatitis C virus. (HIV-positive subjects are ineligible because of the potential for pharmacokinetic interactions of antiviral therapy with IACS-010759.)
Is human immunodeficiency virus (HIV) positive or has evidence of active hepatitis C virus or active hepatitis B virus; if initial test shows a positive result, no further testing will be done
Known positive test for human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis A, hepatitis B, hepatitis C, or cytomegalovirus (CMV)
Known history of human immunodeficiency virus (HIV) positivity or active hepatitis C or B - chronic asymptomatic viral hepatitis is allowed
Human immunodeficiency virus (HIV), active hepatitis B or C
Acute hepatitis or known human immunodeficiency virus (HIV)
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Negative human immunodeficiency virus (HIV), hepatitis B and C, and tuberculosis (TB) test
Human immunodeficiency virus (HIV), hepatitis B or C documented infections
Known human immunodeficiency virus (HIV) or active hepatitis A, B, or C
Active hepatitis B, active hepatitis C, or positive for human immunodeficiency virus (HIV)
Patients with known chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known prior or current history of human immunodeficiency virus (HIV) and/or hepatitis B/C
Serious infections including a history of active hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
Subjects who active hepatitis B or C, or human immunodeficiency virus (HIV)
Known history of active tuberculosis (TB), human immunodeficiency virus (HIV) 1/2, hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV) or active hepatitis C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known human immunodeficiency virus (HIV)-positive and on highly active antiretroviral therapy (HAART), and/or hepatitis B or C on treatment
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), active hepatitis B or hepatitis C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection (note: if not suspected, testing is not required at baseline)
Known history of human immunodeficiency virus (HIV), hepatitis B or C
Patients with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
Known human immunodeficiency virus (HIV) or hepatitis C
An existing diagnosis of human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any current laboratory findings or clinical signs and symptoms that suggest these conditions
Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C that has not been documented to be cured
Positive for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Human immunodeficiency virus (HIV), hepatitis B, hepatitis C
Patients known to be human immunodeficiency virus (HIV)-positive or have active hepatitis B or C
Known positive for human immunodeficiency virus (HIV) or with known active infectious hepatitis, type A, B or C
Known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis (type B or C)
Positive test for hepatitis B hepatitis C, and / or human immunodeficiency virus (HIV) during screening, or within 3 months prior to first dose of study treatment
Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), or hepatitis C.
Patients with known human immunodeficiency virus, active hepatitis B or active hepatitis C
Subject is positive for human immunodeficiency virus (HIV-1) chronic or active hepatitis B, or active hepatitis A or C
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Negative screening test results for hepatitis B, hepatitis C, and human immunodeficiency virus
Patients known positive for human immunodeficiency virus (HIV), or infectious hepatitis type B or C
Known history of human immunodeficiency virus (HIV) or hepatitis C (baseline testing is not required)
Known chronic infections with human immunodeficiency virus (HIV), hepatitis B or C
Subjects with known seropositivity to human immunodeficiency virus (HIV), positive\n for Hepatitis B, positive for Hepatitis C (antigen positive), or known hepatic\n cirrhosis
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Subjects with known history of cirrhosis, human immunodeficiency virus (HIV), hepatitis B or C
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded
Known human immunodeficiency virus (HIV), hepatitis B or C-positive patients (active, previously treated or both)
Patients with human immunodeficiency virus (HIV) disease or active viral hepatitis
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or C
Human immunodeficiency virus (HIV) or hepatitis B or C
Known human immunodeficiency virus (HIV), or Hepatitis B or C.
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
The patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C.
Subjects is positive for human immunodeficiency virus (HIV); chronic or active hepatitis B or active hepatitis A, or C
Positive for human immunodeficiency virus (HIV), Hepatitis B or C
Is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Known active or chronic hepatitis B or C or human immunodeficiency virus (HIV)
Patients with human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C (known from the existing medical record)
Positive human immunodeficiency virus (HIV) or hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Human immunodeficiency virus (HIV), active hepatitis B or C, or tuberculosis
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self-report
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Patients with known history of human immunodeficiency virus (HIV) or hepatitis B
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline by self report
Known history or active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with fever or any active systemic infections, including known human immunodeficiency virus (HIV), hepatitis B or C
Known positive for human immunodeficiency virus (HIV) or hepatitis B or C per institutional standard of care
Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known positive status for human immunodeficiency virus or active or chronic Hepatitis B or Hepatitis C.
Hepatitis B or C or human immunodeficiency virus (HIV)
Known history of human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or C
Known diagnosis of human immunodeficiency virus (HIV) or hepatitis C (testing is not mandatory)
Human immunodeficiency virus (HIV)-positive patients or with history of hepatitis or with current chronic or active hepatitis; a past history of hepatitis A is allowed
Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.
Has a known history of Human Immunodeficiency Virus (HIV) or Hepatitis C (baseline testing is not required).
Known history of human immunodeficiency virus (HIV), active Hepatitis B or C
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Participant is known to be seropositive for human immunodeficiency virus (HIV), known to have hepatitis B surface antigen positivity, or history of to have a history of hepatitis C
Patients must be test negative for human immunodeficiency virus (HIV), hepatitis B and C
Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or hepatitis C virus requiring treatment
Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
Human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis
Patients with known positivity for human immunodeficiency virus (HIV), or hepatitis C; baseline testing for HIV and hepatitis C is not required
Patients with known human immunodeficiency virus (HIV), hepatitis B or hepatitis C (active or carriers)
Hepatitis B or C or known human immunodeficiency virus (HIV) positive
Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C; viral testing is not required; subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment
Patients known to be human immunodeficiency virus (HIV) or hepatitis B and/or C positive are not eligible for participation; NOTE: HIV and hepatitis testing is not required for study participation
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Active human immunodeficiency virus (HIV), hepatitis B and hepatitis C
Negative serology tests for human immunodeficiency virus (HIV) Ab/Ag Combo, and for active hepatitis B or hepatitis C, within 14 days of first peripheral blood collection for sipuleucel-T
Known history of human immunodeficiency virus (HIV), hepatitis B and hepatitis C (testing is not necessary if patient does not have history of these diseases, and no risk factors for acquisition of these viruses)
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C
Active hepatitis C or positive tests for human immunodeficiency virus (HIV)
Patients who are known to be human immunodeficiency virus (HIV), hepatitis B, or hepatitis C positive
Known positivity for human immunodeficiency virus (HIV) or hepatitis C with uncontrolled disease; baseline testing for HIV and hepatitis C is not required
Patient is known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B, or C
Negative virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), and hepatitis C
Positive for HIV (Human Immunodeficiency Virus) or with active hepatitis B and/or C
Subjects known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
Is positive for Human Immunodeficiency Virus (HIV) and/or Hepatitis B or C
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment (note: for guidance in defining active infection for hepatitis B, please refer to the WHO guidelines)
Known human immunodeficiency virus (HIV) and/or active Hepatitis B or C infections
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Known clinically significant infections, including human immunodeficiency virus (HIV) and active hepatitis B or C
Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both)
positive serology for human immunodeficiency virus (HIV), hepatitis B or hepatitis C or have HIV-AIDS, or active hepatitis B or C.
Patients with known human immunodeficiency virus (HIV), or known active hepatitis B or C infections
Patients with known human immunodeficiency virus (HIV) or hepatitis B or C
Positive for human immunodeficiency virus (HIV) or hepatitis B or C
Known positive for human immunodeficiency virus (HIV), chronic or active hepatitis B or active hepatitis A or C
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Clinically significant infections including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required.
Patients with known active hepatitis B, C or human immunodeficiency virus (HIV) infections on initial assessment
Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C
Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type A, B or C
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
Known positive serology for human immunodeficiency virus (HIV), active hepatitis B, and/or active hepatitis C infection
Subjects who are known to have a history of or active human immunodeficiency virus (HIV) or active hepatitis B and/or C
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
Known to be positive for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV), hepatitis B or C (however, if patients have previously been treated for hepatitis B or C and have undetectable viral loads, they can be considered eligible for trial)
Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is not mandatory for study entry)
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections should be excluded because of potential effects on immune function and/ or possible drug interactions
Patients with chronic human immunodeficiency virus (HIV), hepatitis B or hepatitis C infections are excluded
Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis C, and/or active hepatitis B.
The patient has known positive status for human immunodeficiency virus (HIV), active or chronic Hepatitis B or Hepatitis C.
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis C is not required
Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status
Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required; this is due to the unknown effects of AMG102
Patients known to be positive for human immunodeficiency virus (HIV) or infectious hepatitis, type B or C requiring active therapy (hepatitis B seropositivity due to hepatitis [Hep] B virus vaccine is not an exclusion); patients on combination antiviral therapy are ineligible; appropriate studies will be undertaken in this patient population
Human immunodeficiency virus (HIV) positive; active hepatitis B or C
Positive history of human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C or severe/uncontrolled intercurrent illness or infection
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known (historical) positive human immunodeficiency virus (HIV) serology, active hepatitis B, or active hepatitis C infection
Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection
Known history of hepatitis B, C or human immunodeficiency virus (HIV)
Patients must not have known history of hepatitis B, hepatitis C, human immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be approved after consultation with the study chair
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C (testing not required as part of screening)
History of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C
Known chronic active hepatitis B or hepatitis C; human immunodeficiency virus (HIV)-positive patients receiving or are candidates for antiretroviral therapy are also excluded
No known history of human immunodeficiency virus (HIV) or active hepatitis B or C
Patients with a diagnosis of hepatitis or human immunodeficiency virus (HIV)
Patients with known active hepatitis B, hepatitis C, or seropositive human immunodeficiency virus (HIV); testing is not required in the absence of clinical suspicion
History of human immunodeficiency virus (HIV) or active hepatitis C
Known serious infections, including a history of active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV); screening for these infections is not required for study enrollment
Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical history
Subjects with positive human immunodeficiency virus (HIV) or hepatitis C at baseline
Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses
Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B, or active hepatitis A or C
Human immunodeficiency virus (HIV) positive or active hepatitis
Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C =< 1 year prior to registration
Subjects must not have a history of human immunodeficiency virus, hepatitis B, or hepatitis C, except for the following:
Is known to be human immunodeficiency virus (HIV) positive and/or known to have active chronic or acute Hepatitis B or Hepatitis C
Known history of human immunodeficiency virus (HIV), or active Hepatitis B or C.